TY - JOUR T1 - Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease. AU - Toto,Robert, AU - Palmer,Biff F, Y1 - 2007/12/12/ PY - 2007/04/13/received PY - 2007/10/25/accepted PY - 2007/12/13/pubmed PY - 2008/6/24/medline PY - 2007/12/13/entrez SP - 372 EP - 80 JF - American journal of nephrology JO - Am J Nephrol VL - 28 IS - 3 N2 - Chronic kidney disease (CKD) is a major public health problem that has received increasing attention because of the high rate of associated cardiovascular morbidity and mortality. Mounting evidence indicates that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) safely slow down progression of CKD. There is also growing evidence supporting combination treatment of nephropathies with an ACE inhibitor plus an ARB to more completely block the RAAS and provide greater renoprotection than either an ACE inhibitor-based or ARB-based regimen. The National Kidney Foundation suggests that ACE inhibitors and ARBs may be used in combination to reduce proteinuria in patients with kidney disease; however, larger outcomes trials are needed. SN - 1421-9670 UR - https://www.unboundmedicine.com/medline/citation/18073461/Rationale_for_combination_angiotensin_receptor_blocker_and_angiotensin_converting_enzyme_inhibitor_treatment_and_end_organ_protection_in_patients_with_chronic_kidney_disease_ L2 - https://www.karger.com?DOI=10.1159/000112269 DB - PRIME DP - Unbound Medicine ER -